A Placebo Controlled, Randomized, Parallel Cohort, Safety And Tolerability Study Of 2 Dose Levels Of Liposomal Amikacin For Inhalation (Arikace) In Patients With Bronchiectasis Complicated By Chronic Infection Due To Pseudomonas Aeruginosa

Trial Profile

A Placebo Controlled, Randomized, Parallel Cohort, Safety And Tolerability Study Of 2 Dose Levels Of Liposomal Amikacin For Inhalation (Arikace) In Patients With Bronchiectasis Complicated By Chronic Infection Due To Pseudomonas Aeruginosa

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Amikacin (Primary)
  • Indications Bronchiectasis; Pseudomonal infections
  • Focus Adverse reactions
  • Sponsors Transave
  • Most Recent Events

    • 14 Sep 2009 Positive phase II results presented at ERS 2009, according to a Transave media release.
    • 11 Sep 2009 Interim results have been presented at the 19th Annual Congress of the European Respiratory Society.
    • 17 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top